List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3020109/publications.pdf Version: 2024-02-01



REN ROUDSI

#	Article	IF	CITATIONS
1	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 2021, 371, 602-609.	6.0	784
2	Recurrent antibiotic exposure may promote cancer formation – Another step in understanding the role of the human microbiota?. European Journal of Cancer, 2015, 51, 2655-2664.	1.3	233
3	A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology, 2017, 152, 840-850.e3.	0.6	133
4	The effect of past antibiotic exposure on diabetes risk. European Journal of Endocrinology, 2015, 172, 639-648.	1.9	131
5	Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiology and Drug Safety, 2015, 24, 534-542.	0.9	73
6	Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline <i>BRCA</i> Variants. JAMA Oncology, 2021, 7, 693.	3.4	56
7	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Medicine, 2016, 13, e1002007.	3.9	55
8	Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention. Current Pharmaceutical Design, 2007, 13, 2274-2282.	0.9	52
9	Neutrophilâ€ŧoâ€lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer, 2017, 123, 794-801.	2.0	51
10	Thyroid Dysfunction, Thyroid Hormone Replacement and Colorectal Cancer Risk. Journal of the National Cancer Institute, 2015, 107, djv084.	3.0	46
11	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of preâ€COVID‶9 reports. British Journal of Clinical Pharmacology, 2021, 87, 1432-1442.	1.1	45
12	Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiology, 2017, 46, 80-84.	0.8	44
13	The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. European Journal of Cancer, 2013, 49, 3680-3685.	1.3	40
14	Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study. Cancer Immunology Research, 2018, 6, 1453-1458.	1.6	35
15	Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. European Journal of Cancer, 2018, 94, 1-5.	1.3	31
16	Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma. European Journal of Cancer, 2018, 101, 229-235.	1.3	29
17	Total Serum Cholesterol and Pancreatic Cancer: A Nested Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 363-369.	1.1	23
18	Anti-depressant therapy and cancer risk: A nested case-control study. European Neuropsychopharmacology, 2015, 25, 1147-1157.	0.3	21

#	Article	IF	CITATIONS
19	Parkinson's disease and colorectal cancer risk—A nested case control study. Cancer Epidemiology, 2016, 43, 9-14.	0.8	20
20	Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. European Journal of Cancer, 2016, 59, 90-98.	1.3	19
21	Functional imaging of the interaction between gut microbiota and the human host: A proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT. PLoS ONE, 2018, 13, e0192747.	1.1	19
22	Digoxin use and the risk for colorectal cancer. Pharmacoepidemiology and Drug Safety, 2014, 23, 1147-1153.	0.9	17
23	Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. Targeted Oncology, 2021, 16, 471-483.	1.7	17
24	Diagnostic and Prognostic Value of Thrombocytosis in Admitted Medical Patients. American Journal of the Medical Sciences, 2011, 342, 395-401.	0.4	16
25	Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. American Journal of Hematology, 2016, 91, 581-584.	2.0	16
26	A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 33-38.	0.8	16
27	Validation of a Coding Algorithm to Identify Bladder Cancer and Distinguish Stage in an Electronic Medical Records Database. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 303-307.	1.1	15
28	Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Melanoma Research, 2019, 29, 318-321.	0.6	15
29	Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1332-1340.	0.4	15
30	Assessing the effects of betaâ€blockers on pancreatic cancer risk: A nested case ontrol study. Pharmacoepidemiology and Drug Safety, 2020, 29, 599-604.	0.9	13
31	Applications of Fluorodeoxyglucose PET/Computed Tomography in the Assessment and Prediction of Radiation Therapy–related Complications. PET Clinics, 2015, 10, 555-571.	1.5	12
32	Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance. Clinical Cancer Research, 2021, 27, 2074-2086.	3.2	12
33	A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. Digestive Diseases and Sciences, 2016, 61, 2076-2086.	1.1	11
34	Single-Fraction Celiac Plexus Radiosurgery: A Preliminary Proof-of-Concept Phase 2 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 588-593.	0.4	10
35	Association of Itraconazole, a Hedgehog Inhibitor, and Bladder Cancer. Journal of Urology, 2016, 196, 343-348.	0.2	9
36	First report of screening an asymptomatic population for cancer: the yield of an integrated cancer prevention center. Israel Medical Association Journal, 2010, 12, 21-5.	0.1	9

#	Article	lF	CITATIONS
37	Height as an independent anthropomorphic risk factor for colorectal cancer. European Journal of Gastroenterology and Hepatology, 2014, 26, 1422-1427.	0.8	8
38	Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS. Clinical Colorectal Cancer, 2019, 18, e300-e307.	1.0	8
39	Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non- metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Primary outcome analysis of a prospective phase II study Journal of Clinical Oncology, 2019, 37, e16609-e16609.	0.8	8
40	Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Clinical Gastroenterology and Hepatology, 2022, 20, 1997-2004.e7.	2.4	8
41	Pernicious anemia and colorectal cancer risk – A nested case–control study. Digestive and Liver Disease, 2016, 48, 1386-1390.	0.4	7
42	Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 235-239.	0.9	7
43	Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. Clinical Colorectal Cancer, 2019, 18, 226-230.e2.	1.0	7
44	<p>Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review</p> . OncoTargets and Therapy, 2020, Volume 13, 11637-11644.	1.0	7
45	90. Fecal Microbiota Transplantation in Metastatic Melanoma Patients Resistant to Anti-PD-1 Treatment. Open Forum Infectious Diseases, 2019, 6, S7-S7.	0.4	6
46	Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2021, 20, 121-129.	1.0	6
47	Disentangling the association between statins, cholesterol, and colorectal cancer: A nested case-control study Journal of Clinical Oncology, 2016, 34, 3609-3609.	0.8	6
48	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification—Defining novel predictive and prognostic markers in stage III colon cancer. European Journal of Cancer, 2018, 96, 105-110.	1.3	5
49	Posttraumatic Stress Disorder and Cancer Risk: A Nested Caseâ€Control Study. Journal of Traumatic Stress, 2018, 31, 919-926.	1.0	5
50	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. Oncologist, 2019, 24, e671-e676.	1.9	5
51	Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clinical Colorectal Cancer, 2021, 20, 130-136.	1.0	5
52	The Association between Age-Related Macular Degeneration and Renal Cell Carcinoma: A Nested Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 743-747.	1.1	4
53	Impact of antibiotics (ABX) on overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (aNSCLC) and melanoma (aMel) treated with first-line immune checkpoint inhibition (ICI) Journal of Clinical Oncology, 2019, 37, e20643-e20643.	0.8	4
54	Serological response to a third booster dose of BNT162b2 COVIDâ€19 vaccine among seronegative cancer patients. Cancer Reports, 2022, 5, .	0.6	4

#	Article	IF	CITATIONS
55	Tailoring bacterial taxa for immune cell modulation. Hepatobiliary Surgery and Nutrition, 2021, 10, 686-688.	0.7	3
56	An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case–control study. Archives of Dermatological Research, 2016, 308, 661-664.	1.1	2
57	Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?. Molecular and Clinical Oncology, 2019, 10, 555-559.	0.4	2
58	The pattern of peritoneal colorectal metastasis predicts survival after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. European Journal of Surgical Oncology, 2022, 48, 197-203.	0.5	2
59	Ion channel blockers and glioblastoma risk and outcome: a nested case–control and retrospective cohort studies. Pharmacoepidemiology and Drug Safety, 2016, 25, 1179-1185.	0.9	1
60	Digoxin use is associated with pancreatic cancer risk but does not affect survival. Cancer Causes and Control, 2021, 32, 41-46.	0.8	1
61	Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma. Oncologist, 2021, 26, e111-e114.	1.9	1
62	Mortality Among Neutropenic Cancer Patients Within the United States: The Association With Hospital Volume. JCO Oncology Practice, 2021, 17, OP.20.00115.	1.4	1
63	Oxaliplatin immuneâ€mediated thrombocytopenia: Is there a role for premedication or desensitization?. British Journal of Clinical Pharmacology, 2021, , .	1.1	1
64	Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su) Journal of Clinical Oncology, 2012, 30, e15058-e15058.	0.8	1
65	Celiac plexus radiosurgery: A new palliative modality for upper gastrointestinal malignancies—Final results of a proof-of-concept clinical trial Journal of Clinical Oncology, 2018, 36, 10098-10098.	0.8	1
66	The association between proton pump inhibitors (PPI) use for gastro-esophageal reflux disease (GERD) and lung cancer (LC): A nested case-control study Journal of Clinical Oncology, 2017, 35, 1562-1562.	0.8	1
67	Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliative and functional outcomes—Final results of a prospective clinical trial Journal of Clinical Oncology, 2019, 37, 309-309.	0.8	1
68	Accuracy of Smoking Status Reporting. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 801-809.	1.2	1
69	The impact of pancreatic cancer resection in the era of effective systemic treatment Journal of Clinical Oncology, 2020, 38, 722-722.	0.8	1
70	Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC) Journal of Clinical Oncology, 2012, 30, 4619-4619.	0.8	0
71	The APC I1307K polymorphism as a significant risk factor for CRC in average-risk Ashkenazi Jews Journal of Clinical Oncology, 2012, 30, 1507-1507.	0.8	0
72	First report on screening an asymptomatic population for cancer: The yield of an integrated cancer prevention center Journal of Clinical Oncology, 2012, 30, 1564-1564.	0.8	0

#	Article	IF	CITATIONS
73	Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?. Journal of Clinical Oncology, 2013, 31, 453-453.	0.8	0
74	Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D) Journal of Clinical Oncology, 2013, 31, 146-146.	0.8	0
75	Are there geographic differences inÂthe outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?. Journal of Clinical Oncology, 2013, 31, 458-458.	0.8	0
76	APC 11307K polymorphism as a predictive factor for colorectal neoplasia recurrence Journal of Clinical Oncology, 2013, 31, 1526-1526.	0.8	0
77	Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?. Journal of Clinical Oncology, 2013, 31, e15598-e15598.	0.8	0
78	Comparison between the outcome of metastatic RCC patients treated with sunitinib as part of clinical trials and matched nonparticipants receiving sutent as standard therapy Journal of Clinical Oncology, 2013, 31, e15597-e15597.	0.8	0
79	Neurologic, vascular, and endocrine morbidity following childhood exposure to low and moderate doses of ionizing radiation Journal of Clinical Oncology, 2013, 31, 1599-1599.	0.8	0
80	Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) refractory to docetaxel (D) Journal of Clinical Oncology, 2013, 31, e16068-e16068.	0.8	0
81	Association between breast cancer recurrence with immunosuppression in immune-mediated disease: A cohort study Journal of Clinical Oncology, 2016, 34, e13042-e13042.	0.8	0
82	Differences in survival between symptomatic versus asymptomatic recurrence following cystectomy for bladder cancer Journal of Clinical Oncology, 2017, 35, e16021-e16021.	0.8	0
83	A clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes Journal of Clinical Oncology, 2017, 35, e15780-e15780.	0.8	0
84	Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma Journal of Clinical Oncology, 2018, 36, e15686-e15686.	0.8	0
85	Lung metastasis as predictor for prognosis in metastatic colorectal cancer with mutated KRAS Journal of Clinical Oncology, 2019, 37, 636-636.	0.8	0
86	Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database Journal of Clinical Oncology, 2019, 37, 3539-3539.	0.8	0
87	The association between allopurinol use and urologic malignancies: A nested case-control study Journal of Clinical Oncology, 2020, 38, 435-435.	0.8	0
88	Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: Analysis of MOSAIC and C-07 trials Journal of Clinical Oncology, 2020, 38, 118-118.	0.8	0
89	Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	0